Get the Stockscreener App
8.65
0.46%
0.04
After Hours:
8.65
Delcath Systems Inc stock is traded at $8.65, with a volume of 719.76K.
It is up +0.46% in the last 24 hours and down -27.74% over the past month.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
See More
Previous Close:
$8.61
Open:
$8.68
24h Volume:
719.76K
Relative Volume:
0.88
Market Cap:
$304.05M
Revenue:
$2.07M
Net Income/Loss:
$-47.68M
P/E Ratio:
-3.0674
EPS:
-2.82
Net Cash Flow:
$-31.31M
1W Performance:
+0.35%
1M Performance:
-27.74%
6M Performance:
-49.42%
1Y Performance:
-11.19%
1-Day Range:
$8.52
$8.895
1-Week Range:
$8.33
$9.19
52-Week Range:
$8.33
$18.23
Delcath Systems Inc Stock (DCTH) Company Profile
Name
Delcath Systems Inc
Sector
Industry
Phone
(518) 743-8892
Address
566 QUEENSBURY AVENUE, QUEENSBURY, NY
Compare DCTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DCTH
Delcath Systems Inc
|
8.65 | 304.05M | 2.07M | -47.68M | -31.31M | -2.82 |
|
ABT
Abbott Laboratories
|
130.00 | 226.11B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
359.52 | 137.72B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.80 | 123.49B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
BSX
Boston Scientific Corp
|
99.22 | 150.85B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
GEHC
Ge Healthcare Technologies Inc
|
71.02 | 32.17B | 20.25B | 2.29B | 1.40B | 4.8366 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Craig Hallum | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-26-22 | Resumed | Canaccord Genuity | Buy |
| Dec-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Canaccord Genuity | Buy |
| Jan-05-21 | Initiated | BTIG Research | Buy |
| Jun-01-20 | Initiated | Laidlaw | Buy |
View All
Delcath Systems Inc Stock (DCTH) Latest News
Can Delcath Systems Inc. (DV3R) stock attract ESG investmentsJuly 2025 Volume & High Accuracy Swing Entry Alerts - newser.com
What analyst consensus says on Delcath Systems Inc. stockJuly 2025 Catalysts & Verified Momentum Stock Ideas - newser.com
Volatility clustering patterns for Delcath Systems Inc.Breakout Watch & Free Growth Oriented Trading Recommendations - newser.com
How supply shortages influence Delcath Systems Inc. (DV3R) stockWall Street Watch & Low Risk Growth Stock Ideas - newser.com
Delcath Systems (DCTH) Highlights Promising Results for Liver Me - GuruFocus
Delcath (Nasdaq: DCTH) PHP Review Reports Up to 89% Disease Control in Uveal Melanoma - Stock Titan
H.C. Wainwright Reiterates a Buy on Delcath Systems (DCTH), Lowers the PT - Insider Monkey
10 Fast-Growing Small Cap Stocks to Buy According to Analysts - Insider Monkey
Why Delcath Systems Inc. (DV3R) stock trades below fair valueWeekly Trend Recap & Free Risk Controlled Daily Trade Plans - newser.com
How Delcath Systems Inc. (DV3R) stock reacts to Fed tighteningAnalyst Upgrade & Stock Market Timing Techniques - newser.com
Delcath Systems Reports Positive CHOPIN Trial Results - MSN
Will Delcath Systems Inc. benefit from macro trendsMarket Movement Recap & Community Supported Trade Ideas - newser.com
Can Delcath Systems Inc. (DV3R) stock beat analyst consensusJuly 2025 Review & Daily Technical Forecast Reports - newser.com
Will Delcath Systems Inc. (DV3R) stock issue positive guidanceJuly 2025 Reactions & Long-Term Growth Plans - newser.com
Is it time to cut losses on Delcath Systems Inc.Quarterly Market Summary & Weekly Stock Breakout Alerts - newser.com
Real time breakdown of Delcath Systems Inc. stock performanceJuly 2025 Breakouts & Long Hold Capital Preservation Plans - newser.com
How to use a screener to detect Delcath Systems Inc. breakoutsTrade Entry Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Evaluating Delcath Systems Inc. with trendline analysisFed Meeting & High Conviction Trade Alerts - newser.com
Will Delcath Systems Inc. stock reach all time highs in 20252025 Technical Overview & Stock Timing and Entry Methods - newser.com
Delcath Systems announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Delcath Systems (NASDAQ:DCTH) CEO Gerard Michel Acquires 11,500 Shares of Stock - MarketBeat
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients - BioSpace
Can volume confirm reversal in Delcath Systems Inc.Weekly Market Outlook & Weekly High Return Stock Opportunities - newser.com
Los Angeles Capital Management LLC Purchases New Holdings in Delcath Systems, Inc. $DCTH - MarketBeat
Delcath Systems Inc DV3R Stock Analysis and ForecastQuarterly Earnings Review & Trade Like a Pro Using AI Edge - earlytimes.in
Study suggests early liver-directed therapies improve survival in melanoma By Investing.com - Investing.com Nigeria
Delcath Systems CEO Michel buys $98k in shares By Investing.com - Investing.com Nigeria
Insider Buying: Gerard Michel Acquires Shares of Delcath Systems Inc (DCTH) - GuruFocus
Delcath Systems CEO Michel buys $98k in shares - Investing.com
Delcath Systems Shares Tick Higher After Study Highlights Strong Outcomes for Liver Cancer Treatment - MSN
Delcath Systems (DCTH) Study Highlights Promising Liver Therapy for Cancer Patients - GuruFocus
Delcath Systems stock rises after positive study results on liver cancer treatment - Investing.com
Study suggests early liver-directed therapies improve survival in melanoma - Investing.com
Delcath Systems Inc Stock (DCTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.26%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):